Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece
Cost was impacted by type of systemic treatment; 2 L treatment costs were lower as a higher proportion of patients were treated with chemotherapy rather than NHAs.
Authors
- Davide Mauri (ORCID: https://orcid.org/0000-0002-8501-5986)
- Evangelos Bournakis
- Alexandros Ardavanis
- Marinos Tsiatas (ORCID: https://orcid.org/0000-0002-5881-992X)
- Flora Zagouri (ORCID: https://orcid.org/0000-0001-7153-6556)
- Alkistis Papatheodoridi (ORCID: https://orcid.org/0000-0001-6248-6964)
- A Bournakis
- C Christodoulou
- G. Emmanouil
- Ioannis Binas
- Konstantinos Karalis (ORCID: https://orcid.org/0000-0003-2835-9384)
- Roubini Zakopoulou (ORCID: https://orcid.org/0000-0001-8301-8879)
- Yannis Dimitriadis (ORCID: https://orcid.org/0000-0001-7275-2242)
- Aristotle Bamias
- E. Kostouros
- A. Andrikopoulou
- Areti Mamali
- D.V Zolota
Institutions
- University of Ioannina (GR)
- National and Kapodistrian University of Athens (GR)
- General Hospital of Athens G. Genimatas (GR)
- Alexandra Hospital (GR)
- St Savas Hospital (GR)
- Athens Medical Center (GR)
- University General Hospital Attikon (GR)
- Metropolitan Hospital (GR)
- Anticancer Fund (BE)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1080/14737167.2025.2505726
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52